Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02278783 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer
A Phase 2 study, sponsored by University of Utah.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT02278783 is a Phase 2 study that was terminated before completion, run by University of Utah. The registered enrollment target is 1 participants.
The verdict
NCT02278783, a Phase 2 study, was terminated before completion, sponsored by University of Utah.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This will be a non-blinded, single arm study to test the efficacy of Regorafenib in patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer.
Interventions
- DRUG regorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2015-03 |
| Est. Completion | 2017-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02278783
The ClinicalTrials.gov registry entry for NCT02278783 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which regorafenib is the first listed.
NCT02278783 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02278783 about?
NCT02278783 is a clinical study titled "Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer". This will be a non-blinded, single arm study to test the efficacy of Regorafenib in patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer.
What is the current status of trial NCT02278783?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2015-03. Estimated completion is 2017-01.
What interventions are being tested in trial NCT02278783?
The interventions under investigation include: regorafenib (DRUG).
Who is sponsoring clinical trial NCT02278783?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.